MedTrace Logo

Voxelotor Sickle Cell Exercise Study

NCT04581356 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2022-06-15

No results posted yet for this study

Summary

This study is a pilot, open-label, single-arm study to evaluate the effect of the sickle cell medication voxelotor on exercise capacity, as measured by cardiopulmonary exercise testing (CPET) in patients 12 years of age and older with sickle cell anemia (SCA).

Conditions

Interventions

DRUG

Voxelotor

daily voxelotor 1500mg oral medication

Sponsors & Collaborators

Principal Investigators

  • Elizabeth Yang, MD, PhD. · Pediatric Specialists of Virginia

  • Vivian Phan, MS · Pediatric Specialists of Virginia

  • Kari Wheeler, BSN, RN · Pediatric Specialists of Virginia

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-21
Primary Completion
2021-10-25
Completion
2021-12-29
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04581356 on ClinicalTrials.gov